Suppr超能文献

酒精性肝病中的膳食胆固醇。

Dietary cholesterol in alcohol-associated liver disease.

作者信息

Jia Lin

机构信息

Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX, USA.

出版信息

Immunometabolism (Cobham). 2023 May 3;5(2):e00026. doi: 10.1097/IN9.0000000000000026. eCollection 2023 Apr.

Abstract

There is an increasing prevalence of alcohol-associated liver disease (ALD) worldwide. In addition to excessive alcohol consumption, other nutritional factors have been shown to affect the initiation and progression of ALD. The emerging role of cholesterol in exacerbating ALD has been reported recently and the underlying mechanisms are discussed. In addition, the interplay between dietary cholesterol and alcohol on cholesterol metabolism is reviewed. Furthermore, we highlight the therapeutic potential of cholesterol-lowering drugs in managing the onset and severity of ALD. Finally, we suggest the future mechanistic investigation of the effect of cholesterol on insulin resistance and intestinal inflammation in the exacerbation of alcohol-induced cellular and systemic dysfunction.

摘要

全球范围内,酒精性肝病(ALD)的患病率呈上升趋势。除过量饮酒外,其他营养因素也已被证明会影响ALD的发生和发展。最近有报道称胆固醇在加重ALD方面发挥着新作用,并对其潜在机制进行了讨论。此外,还综述了膳食胆固醇与酒精在胆固醇代谢方面的相互作用。此外,我们强调了降低胆固醇药物在控制ALD的发生和严重程度方面的治疗潜力。最后,我们建议未来对胆固醇在酒精诱导的细胞和全身功能障碍加重过程中对胰岛素抵抗和肠道炎症影响的机制进行研究。

相似文献

1
Dietary cholesterol in alcohol-associated liver disease.
Immunometabolism (Cobham). 2023 May 3;5(2):e00026. doi: 10.1097/IN9.0000000000000026. eCollection 2023 Apr.
2
Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives.
Biomedicines. 2022 Oct 10;10(10):2530. doi: 10.3390/biomedicines10102530.
3
Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives.
Int J Mol Sci. 2021 May 13;22(10):5170. doi: 10.3390/ijms22105170.
4
Targeting the gut barrier for the treatment of alcoholic liver disease.
Liver Res. 2017 Dec;1(4):197-207. doi: 10.1016/j.livres.2017.12.004.
5
Alcohol-associated liver disease: Epidemiology and management.
Ann Hepatol. 2024 Jan-Feb;29(1):101162. doi: 10.1016/j.aohep.2023.101162. Epub 2023 Oct 12.
6
Intersection of Coronavirus Disease 2019 and Alcohol-associated Liver Disease: A Review of Emerging Trends and Implications.
Clin Ther. 2023 Dec;45(12):1164-1170. doi: 10.1016/j.clinthera.2023.08.019. Epub 2023 Sep 26.
7
Stearic acid prevent alcohol-induced liver damage by regulating the gut microbiota.
Food Res Int. 2022 May;155:111095. doi: 10.1016/j.foodres.2022.111095. Epub 2022 Mar 5.
9
Dietary supplementation in patients with alcoholic liver disease: a review on current evidence.
Hepatobiliary Pancreat Dis Int. 2016 Aug;15(4):348-60. doi: 10.1016/s1499-3872(16)60096-6.
10
Immune dysregulation and pathophysiology of alcohol consumption and alcoholic liver disease.
Rev Gastroenterol Mex (Engl Ed). 2023 Apr-Jun;88(2):136-154. doi: 10.1016/j.rgmxen.2023.03.003. Epub 2023 Mar 25.

本文引用的文献

1
Prevalence and associations of metabolic syndrome in patients with alcohol use disorder.
Sci Rep. 2022 Feb 16;12(1):2625. doi: 10.1038/s41598-022-06010-3.
2
Is there a role of lipid-lowering therapies in the management of fatty liver disease?
World J Hepatol. 2022 Jan 27;14(1):119-139. doi: 10.4254/wjh.v14.i1.119.
3
Role of Cholesterol-Associated Steatohepatitis in the Development of NASH.
Hepatol Commun. 2022 Jan;6(1):12-35. doi: 10.1002/hep4.1801. Epub 2021 Aug 24.
4
Association between alcohol dietary pattern and prevalence of dyslipidaemia: WASEDA'S Health Study.
Br J Nutr. 2022 Jun 14;127(11):1712-1722. doi: 10.1017/S0007114521002671. Epub 2021 Jul 14.
5
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis.
Prog Lipid Res. 2021 Jul;83:101109. doi: 10.1016/j.plipres.2021.101109. Epub 2021 Jun 11.
6
Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis.
PLoS One. 2020 Jul 23;15(7):e0235990. doi: 10.1371/journal.pone.0235990. eCollection 2020.
7
Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study.
Lancet Public Health. 2020 Jun;5(6):e316-e323. doi: 10.1016/S2468-2667(20)30062-1.
8
PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease.
Sci Rep. 2019 Nov 20;9(1):17167. doi: 10.1038/s41598-019-53603-6.
10
Immunometabolic function of cholesterol in cardiovascular disease and beyond.
Cardiovasc Res. 2019 Jul 1;115(9):1393-1407. doi: 10.1093/cvr/cvz127.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验